India’s dependence on imported APIs

1. At a Glance

• API (Active Pharmaceutical Ingredient) = the biologically active component of a drug; India, the "Pharmacy of the World" in formulations, is paradoxically a net importer of APIs/bulk drugs. [S1]
• In FY 2024-25, India imported 200 categories of APIs/bulk drugs/drug intermediates worth ~USD 4.35 billion, with China supplying ~73.7% — a strategic vulnerability for health security and trade. [S1]
• Relevant for GS-II (Health, Govt schemes) and GS-III (Economy, Industrial policy, Supply-chain security).

2. Why in the News

• PIB release dated 3 Feb 2026 by Ministry of Chemicals & Fertilizers, Dept. of Pharmaceuticals placing FY24-25 API import data in Parliament and flagging geopolitical/supply-chain risks. [S1]
• Renewed focus on Aatmanirbhar Bharat in pharma after Red Sea disruptions and China-route concentration concerns.

3. Background & Evolution

• 1970s-80s: India was largely self-sufficient in bulk drugs (Indian Patents Act 1970 + Drug Price Control Order regime).
• Post-2000: Cheaper Chinese KSMs eroded domestic bulk-drug capacity; formulations industry grew while upstream API base shrank.
• March 2020: Cabinet approved twin schemes — PLI for Bulk Drugs and Promotion of Bulk Drug Parks — triggered by COVID-19 supply shocks. [S2][S3]
• 2023: PRIP (Promotion of Research & Innovation in Pharma-MedTech) scheme launched. [S2]

4. Core Static Facts

• Nodal ministry: Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers. [S1]
• PLI Scheme for Bulk Drugs: outlay ₹6,940 crore; tenure FY2022-23 to FY2028-29; covers 41 identified critical bulk drugs (KSMs/DIs/APIs). [S2]
• As of Dec 2024: 48 projects selected, 34 commissioned, producing 25 bulk drugs. [S2]
• Cumulative investment ~₹4,570 crore (vs committed ₹3,938.5 cr) by Year-3. [S2]
• Bulk Drug Parks Scheme (Cabinet approval 20 Mar 2020): 3 parks in Himachal Pradesh (Una), Gujarat (Bharuch), Andhra Pradesh (East Godavari). [S3]
• Grant: 70% of common infrastructure cost (Gujarat/AP); 90% for Himachal (hilly state); cap ₹1,000 crore/park. [S3]
• Import value FY24-25: ~USD 4.35 bn; China share 73.7%. [S1]
• High-import therapeutic segments: antibiotics, anti-fungal, anti-amoebic, GI disorders, antidiabetic, endocrine/hormonal, cardiovascular, oncology, female infertility/contraception, neurology, essential amino-acid deficiency. [S1]

5. Multi-Dimensional Analysis

Economic - API imports of $4.35 bn widen pharma trade deficit upstream though formulation exports remain strong. [S1] - PLI investments of ₹4,570 cr signal capacity revival but China cost arbitrage persists. [S2]

Geopolitical / Strategic - 73.7% China concentration is a single-point-of-failure risk amid LAC tensions and global de-risking. [S1] - Implicates health security akin to a strategic commodity (parallels semiconductors, rare earths).

Scientific / Technological - Fermentation-based KSMs (penicillin G, 7-ACA) require scale + cheap utilities + environmental clearances — areas where China leads. - PRIP scheme targets innovation gap in complex generics, biologics, phytopharma. [S2]

Administrative / Federal - Bulk Drug Parks deploy centre-state co-financing with state-led land/utility provisioning (HP, Gujarat, AP). [S3] - Environmental clearance bottlenecks for solvent-intensive units remain a state-level chokepoint.

Ethical / Governance - Affordability of essential medicines depends on stable API supply; concentration risk → price spikes (e.g., paracetamol during COVID).

6. Recent Developments (last 12-18 months)

• 3 Feb 2026 — PIB statement quantifying FY24-25 API import dependence (USD 4.35 bn; China 73.7%). [S1]
• March 2025 — PLI Bulk Drugs cumulative investment crossed committed threshold (₹4,570 cr). [S2]
• Dec 2024 — 34 of 48 PLI projects commissioned, 25 bulk drugs under domestic production. [S2]

7. Prelims Hooks

• API import bill FY24-25: ~USD 4.35 billion across 200 HSN categories. [S1]
• China's share of India's API imports: ~73.7%. [S1]
• Nodal department: Department of Pharmaceuticals, Min. of Chemicals & Fertilizers (not Min. of Health). [S1]
• PLI Bulk Drugs outlay: ₹6,940 crore; targets 41 critical KSMs/DIs/APIs. [S2]
• PLI Bulk Drugs tenure: FY 2022-23 to FY 2028-29. [S2]
• Bulk Drug Parks Scheme approved by Cabinet on 20 March 2020. [S3]
• States selected for Bulk Drug Parks: Himachal Pradesh, Gujarat, Andhra Pradesh. [S3]
• Max central assistance per Bulk Drug Park: ₹1,000 crore. [S3]
• Grant rate: 70% (Gujarat/AP), 90% (Himachal — hilly state). [S3]
• Bulk Drug Park sites: Una (HP), Bharuch-Jambusar (Gujarat), East Godavari (AP). [S3]
• PRIP = Promotion of Research & Innovation in Pharma-MedTech. [S2]
• Therapeutic segments with high import dependence include antibiotics, oncology, cardiovascular, antidiabetic. [S1]

8. Mains Relevance

• GS-III: Indian Economy — Industrial policy; Mobilisation of resources; Investment models. GS-II: Health; Government schemes.
• Syllabus hooks: "Issues related to planning, mobilisation of resources"; "Issues relating to development and management of Health".
• Probable stems: 1. "India's status as the 'pharmacy of the world' is undermined by deep upstream API dependence on a single country. Examine the policy response." (GS-III, 250 words) 2. "Discuss how PLI and Bulk Drug Parks schemes seek to address supply-chain vulnerabilities in India's pharmaceutical sector." (GS-III) 3. "Strategic autonomy in essential medicines is a national security concern. Comment." (GS-II/III)

9. Related Topics to Study Next

• PLI Schemes (14 sectors) — flagship industrial policy tool.
• Jan Aushadhi (PMBJP) — affordability link to API costs.
• Indian Patents Act 1970 & TRIPS — historical roots of bulk-drug capacity.
• National Pharmaceutical Pricing Authority (NPPA) & DPCO — price control mechanism.
• Rare-earth & semiconductor import dependence — parallel supply-chain stories.
• India-China trade deficit — macro context.
• Quad Supply Chain Resilience Initiative — geopolitical de-risking.
• DPIIT FDI policy in pharma — 100% FDI auto for greenfield, govt route for brownfield.

10. Common Errors / Trap Areas

• Ministry confusion: Pharma sits under Chemicals & Fertilizers, NOT Ministry of Health. [S1]
• Bulk Drug Parks states: only 3 (HP, Gujarat, AP) — not Telangana/Maharashtra despite pharma hubs. [S3]
• PLI Bulk Drugs vs PLI Pharma: separate schemes with different outlays (₹6,940 cr vs ₹15,000 cr).
• API ≠ Formulation: India exports formulations but imports the API inside them.
• China share is ~74% of API imports — not of total pharma imports or value of medicines consumed.

11. Sources

• [S1] Ministry of Chemicals and Fertilizers — India's dependence on imported APIs (PIB, 03 Feb 2026, PRID 2222528) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2222528 — (tier 1)
• [S2] PIB — Strengthening pharmaceutical self-reliance / PLI Bulk Drugs status — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2158120 — (tier 1)
• [S3] PIB — Centre Grants 'in-Principle' Approval of three Bulk Drug Parks to Himachal Pradesh, Gujarat and Andhra Pradesh — https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=1856080 — (tier 1)